SOCIUM Inc. started its operations in September 2017 with a corporate mission,“Drug discovery for patients with no drug, Drug discovery for patients with ineffective drug.”

“socium” means “Partner” in Latin. SOCIUM committed to being a partner with people that hope to enjoy healthier life.

We have a precise understanding of the challenges associated with drug discovery and provide optimal solutions based on our proven proprietary technologies.

Simultaneously, we utilize these proprietary technologies to identify existing drugs that demonstrate efficacy for diseases lacking treatment options, particularly rare diseases. Our aim is to swiftly bring these treatments to patients through borderless co-development initiatives.

Member

Katsuhisa HORIMOTO, Ph.D.

Board Director CEO, Founder

Tokyo Univ. of Science, Ph.D.(Biophysics),The Univ. of Tokyo, AIST
>130 peer-reviewed papers on computational systems biology, 8 parents of algorithms.
2017/9 Co-founder of Socium.
2019/4 Invited Researcher of AIST, Visiting Professor of Saitama Medical Univ.

Michio SHIGEMORI, MBA

Board Director, CFO

Meiji Univ., MBA
Worked in global treasury services at Bank of America and treasury operations at BASF Metals Japan.
2022/6 Joined Socium
2024/1 Board Director CFO

Noboru IWAKAMI, Ph.D.

Board Director, CMO

Waseda Univ., Ph.D.(Human Science)
Worked at Toyama Chemical Co., Ltd., in charge of research and development in the field of psychiatry and neurology.
2021/11 Joined Socium
2024/1 Board Director CMO

Makoto MIURA

Audit & Supervisory Board Member

Graduated from the Univ. of Tokyo, Faculty of Economics.
Worked in U.S. GAAP auditing of megabanks at Deloitte Touche Tohmatsu LLC and Established Makoto Miura CPA Office.
2018/10 Joined Socium

Company Profile

Company NameSOCIUM Inc.
Segments Drug repositioning platform based on a combination of proprietary technologies, and the world’s first phosphorylation analysis technology
  • Drug Repurposing(Indication Hopping)
  • Phosphorylation Analysis(activating pathway and kinase analysis)
  • MOA Clarification
  • Target Prediction
  • Stratification Marker Exploration
  • in silico Screening
  • in vitro, vivo assay
and,
joint development of drug seeds discovered using these technologies
CEOKatsuhisa Horimoto
Office17-1, Nihonbashi-Kabuto-cho, Chuo-ku, Tokyo 103-0026, Japan
LaboratoryAIST Tokyo Waterfront, 2-4-7, Aomi, Koto-ku, Tokyo 135-0064, Japan
google map

Career

Click here for Career Information